50% for giant posterior circulation UIAs. A recent morphometric analysis of aneurysms in the ISUIA revealed that, in addition to the previously reported risk factors of aneurysm size and location, the perpendicular height of the aneurysm and its size ratio (i.e., ratio of maximum aneurysm diameter to parent vessel diameter) were also important predictors of UIA rupture risk. 25 Given the high rupture risk associated with giant (diameter > 25 mm) UIAs, treatment of these lesions should be considered.
Since the introduction of extracranial-intracranial bypass for the treatment of cerebral ischemia by Yasargil et al. 47, 48 in the 1970s, the indications for revascularization have expanded to the treatment of complex and giant aneurysms, which became popularized in the 1980s. 39, 41, 42 The International Subarachnoid Aneurysm Trial (ISAT) 26, 27 and Barrow Ruptured Aneurysm Trial (BRAT) 24, 37, 38 reported better interim and long-term outcomes with endovascular therapy than with surgical clipping for ruptured aneurysms. However, no randomized trials have compared endovascular versus surgical treatment for UIAs, and most of the literature pertaining to UIAs is in the form of retrospective series and meta-analyses. 3, 10, 14, 31, 34, 36 Technological advances in endovascular therapy have led to an increase in endovascular procedures as the treatment of choice for cerebral aneurysms, from 20% of all aneurysms in 2001 to 63% in 2008. 7 The introduction of flow-diverting stents has afforded neuroendovascular surgeons the opportunity to treat otherwise challenging aneurysms (e.g., giant, recurrent, fusiform, dissecting) by endoluminal reconstruction of the affected parent vessel, which results in progressive aneurysm occlusion over time while preserving flow through the parent artery. 4, 13, 21, 30 Since substantial overlap may exist between UIAs treated with surgical bypass and those treated with endovascular flow diversion, we hypothesized that the advent and subsequent dissemination of flow diverters, specifically the Pipeline embolization device (PED; Medtronic Neurovascular) which was approved by the United States (US) Food and Drug Administration (FDA) in April 2011, may be associated with a decline in the utilization of bypass for UIAs. Therefore, the aim of this retrospective cohort study was to evaluate temporal trends in cerebral revascularization procedures for UIAs in the US by using the National (Nationwide) Inpatient Sample (NIS), with particular consideration of the modern flow diversion era.
Methods

Data Source
We extracted data from the Healthcare Cost and Utilization Project (HCUP) NIS, which was established as a federal-state-industry partnership sponsored by the Agency for Healthcare Research and Quality (AHRQ) and is the largest all-payer inpatient care database. Data are released annually, dating back to 1988. Prior to 2012, the NIS data represented a 20% stratified sample of nonfederal community hospitals in the US. Beginning in 2012, the NIS approximates a 20% sample of all discharges from community hospitals (excluding rehabilitation and long-term acute care hospitals) in the US. Weights are provided to obtain national estimates. Unweighted, the NIS comprises approximately 7 million hospital stays per year. Weighted, the NIS represents about 35 million hospital stays per year. The discharge abstract includes both the Clinical Classification Software (CCS) and International Classification of Diseases, 9th and 10th Revisions (ICD-9/10) diagnostic and procedure codes.
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The data contain information regarding admission and discharge status, demographic data, charges, length of stay, geographic locations, complications, and mortality. The NIS has been used to analyze national trends in healthcare use and charges, in quality and outcomes, and in policy. 15, 16, 22, 23, 28, 32, 44 For this study, we used NIS data from 1998 to 2015.
Case Selection
Cases were hospitalizations in which patients had a primary diagnosis code of "cerebral aneurysm, nonruptured" (ICD-9 code 437.3 or ICD-10 code I671) with a concurrent procedure code of "bypass" (ICD-9 code 39.28 or ICD-10 codes 031G, 031H, 031J, 031K, 031L, 031M, 031N, 031S, 031T).
Patient Characteristics
The following patient characteristics were extracted: age, sex, race/ethnicity, comorbidity score, median household income by zip code, and primary payer. The comorbidity score was measured with the Elixhauser comorbidity index, 12 whose score was computed using an adaptation to ICD-9 and ICD-10 codes developed by Quan et al.
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The median household income by zip code was categorized in quartiles, from 1 (lowest) to 4 (highest).
Hospital Characteristics
The following hospital characteristics were extracted: hospital bed size (small, medium, or large), hospital region (Northeast, Midwest/North Central, South, or West), hospital location and/or teaching status (rural, urban nonteaching, or urban teaching), and admission/service type (emergent or elective).
In-Hospital Outcomes
The outcomes were length of stay, hospital charges, and complications. Hospital charges were adjusted to 2015 US$ using the Medicare care component of the consumer price index (accessible through the Bureau of Labor Statistics). In our analysis, we included diagnosis codes for the following complications: renal, cardiac, neurological, neurosurgical, deep vein thrombosis and/or pulmonary embolism, infection, wound, hydrocephalus, mechanical ventilation, pneumonia, and laceration. The ICD-9 and ICD-10 codes were used to survey complications.
Statistical Analysis
Continuous variables were summarized as the mean with standard deviation or the median with interquartile range and full range, as appropriate. Categorical variables and outcomes were summarized as the frequency count and percentage. For statistical comparisons, we used gen-eralized linear models adjusted for the clustered and stratified nature of the data. To determine whether there was a specific year during which the trend significantly changed, we used Joinpoint Regression. The significance level was set to a p value < 0.05, and all statistical tests were twosided. Data analyses were performed using SAS (SAS Institute) and Joinpoint Regression Software 
Results
The study cohort comprised 216,212 patients with a primary diagnosis of UIA during the study period. Table  1 details the number of primary diagnosis codes for UIA and the number of primary or secondary procedure codes for bypass for each year of the study period (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) . The number of patients with UIA as the primary diagnosis increased by 128% from 1998 (n = 7718) to 2015 (n = 17,600). However, the yearly proportion of UIA patients undergoing cerebral bypass remained stable during the study period ( Fig. 1) , ranging from 0.3% (1998) to 1.8% (1999). In the more recent flow diverter era (2010) (2011) (2012) (2013) (2014) (2015) , the annual percentage of UIA patients undergoing bypass remained stable at approximately 0.4% (Fig. 2) .
Patient Demographics and Cerebral Bypass
A total of 1328 UIA patients (0.6% of the study cohort) underwent cerebral bypass. Table 2 summarizes the demographics of the study cohort, compares the demographics of UIA patients with versus without bypass, and compares the demographics of UIA patients who underwent bypass in 1998-2011 versus 2012-2015. The UIA patients who underwent bypass were younger (median age 56 vs 57 years, p < 0.0001), and if the UIA patient was male, they were more likely to undergo bypass (38% vs 26%, p < 0.0001). The majority of patients who underwent bypass for UIA were white (51%), had an Elixhauser comorbidity index ≥ 3 (51%), had a median household income in the 3rd or 4th quartile (57%), and were privately insured (51%). Significant differences between UIA patients who underwent bypass and those who did not were observed for race/ethnicity (p < 0.0001), comorbidity index (p = 0.0035), median household income (p < 0.0001), and insurance (p < 0.0001). We also found significant differ- ences in race/ethnicity (p < 0.0001), comorbidity index (p = 0.0071), median household income (p < 0.0001), and insurance (p < 0.0001) between patients who underwent bypass in 1998-2011 and those who did so in 2012-2015. Table 3 summarizes the hospital characteristics of the study cohort, compares the hospital characteristics of UIA patients with versus without bypass, and compares the hospital characteristics of UIA patients who underwent bypass in 1998-2011 versus 2012-2015. When considering geographic distribution, the majority of bypass procedures were performed in the West (33%) and Midwest/ North Central region hospitals (30%), with Northeast region hospitals performing the least (15%). In this 17-year patient sample, most bypass procedures for UIAs were performed at large (83%) and urban teaching (96%) hospitals and on an elective basis (67%). Compared to the time period of 1998-2011, bypass procedures for UIAs in the years 2012-2015 shifted entirely to urban teaching hospitals (100%) and were more frequently performed on an elective basis (77%).
Hospital Characteristics and Cerebral Bypass
Significant differences were observed in hospital bed size (p < 0.0001), hospital region (p < 0.0001), hospital location and teaching status (p < 0.0001), and admission/ service type (p < 0.0001) between UIA patients who underwent bypass and those who did not. We also found significant differences in hospital bed size (p = 0.0089), hospital region (p = 0.0003), hospital location and teaching status (p = 0.0003), and admission/service type (p < 0.0001) between patients who underwent bypass for UIA in 1998-2011 and those who did so in 2012-2015. Table 4 summarizes the length of stay, hospital costs, and postoperative complications of the study cohort, compares these factors between UIA patients with and those without bypass, and compares these factors between UIA patients who underwent bypass in 1998-2011 and those who did so in 2012-2015. The median hospital stay (9 vs 3 days, p < 0.0001) and median hospital charges ($186,746 vs $66,361, p < 0.0001) were three times greater for the UIA patients who underwent bypass than for those who did not. The rate of any complication was also three times higher in the UIA patients who underwent bypass (51% vs 17%, p < 0.0001).
Length of Stay, Hospital Costs, and Complications Following Bypass for UIA
Compared to the years 1998-2011, the median length of stay following bypass for UIA remained unchanged in 2012-2015 (9 vs 8 days, respectively, p = 0.1660). However, the median cost of hospitalization for bypass in UIA pa- 
Discussion
In this retrospective cohort study, whose data were derived from an analysis of the NIS for the period from 1998 to 2015, we found that cerebral bypass continues to be performed in a very small proportion of UIA patients in the US. Despite the introduction of endovascular flow diversion for the treatment of UIA, 5 the annual rates of bypass procedures performed for UIAs remained stable at a low rate (mean 0.4%), even in the context of an increased frequency of UIA diagnosis by 128% during the study period.
Our findings reject the supposition that the application and dissemination of flow diverters for UIAs have reduced the utilization of bypass as a treatment method. As shown by our results, the percentage of patients undergoing cerebral bypass for UIAs has remained largely unchanged between 1998 and 2015, with no change in trends since FDA approval of the PED in 2011. Bypass is still overwhelmingly performed by large academic hospitals, which may be due to the procedure's technical complexity and the relatively few neurosurgeons who have retained expertise in the procedure. 17 Our study showed that bypass procedures for the treatment of UIAs have shifted entirely to urban teaching hospitals in the time period 2012-2015. This may reflect a consolidation of referral patterns toward high-volume academic centers of excellence. 1, 2, 17, 33, 39 Our analysis has shown that the bypass is predominantly performed in individuals with an Elixhauser comorbidity index of 2 or greater (77%) and is virtually never performed in individuals with a score of 0. This suggests that certain comorbidities may play a role in the progression of aneurysms to the complex lesions requiring bypass. Unsurprisingly, bypass correlated with significantly longer hospital stays and admission costs. This could be related to a more intensive use of resources or the inherent complexity of UIAs not amenable to more conventional treatments such as endovascular therapy or surgical clipping.
A noticeable finding was the much higher complication rates in patients undergoing bypass than in those who did not (51% vs 17%, p < 0.0001). This difference could be partly explained by the previously noted difference in the prevalence of comorbidities between the two groups, making patients in the bypass group more vulnerable to complications arising from preexisting medical problems. This difference could also be attributed to an increased operative morbidity associated with bypass procedures and the technical complexities arising from the lesions themselves. 17 It should also be noted that the overall complication rate in patients undergoing bypass has gradually decreased over time. This could be explained by improvements in surgical techniques, the patient concentration in high-volume academic centers, and changes in the selection criteria for bypass in light of emerging endovascular options. 40 Our results challenge the notion that the emergence of flow diversion has decreased the need for cerebral bypass in the contemporary management of UIAs not amenable to endovascular coiling or surgical clipping, which implies that many of those complex lesions that warrant bypass surgery are still not amenable to flow diversion or other novel endovascular devices. Despite its high costs and need for prolonged hospitalization, cerebral bypass remains necessary for certain aneurysms with challenging anatomy or giant aneurysms, both of which are poor candidates for flow diversion. 35 Bypass appears to provide a high cure rate with good vessel patency in appropriately selected patients 18 and continues to represent an acceptable alternative for aneurysms that are otherwise untreatable by other means. Therefore, training future generations of vascular neurosurgeons in developing and maintaining proficiency in this surgical technique is paramount in keeping this modality available for these complicated aneurysms.
We can hypothesize, based on FDA approval of the PED for proximal internal carotid artery aneurysms from the petrous to superior hypophyseal segments, that more 4 (14) 4 (13) 14 (35) 15 (37) 12 (25) Median (Q1-Q3) recent bypasses may be used more frequently for distally located aneurysms (e.g., anterior cerebral artery, middle cerebral artery, posterior inferior cerebellar artery) for which flow diversion has not yet been proven or accepted as the preferred treatment. 5, 50 Based on the available literature, there does not appear to be a substantial change in the rates of graft vessel patency over time (i.e., pre-45 vs post-PED 43,49 eras), although recent publications from the US have suggested an increasing preference for the radial artery as the interposition graft of choice rather than the saphenous vein. 6, 9, 11, 33 However, we emphasize that these trends are inferred from the literature and cannot be informed by the NIS database used in this study.
Study Strengths and Limitations
The NIS provides a large sample size and an opportunity to look at the trends and practice patterns across the US. Researchers who query this database can answer a question in a comprehensive manner. The NIS also provides inpatient outcomes and hospitalization charges.
Limitations associated with the NIS include those associated with a retrospective cohort study (e.g., selection, treatment, and referral biases), coding errors, underestimation of mortality, and an inability to provide detailed long-term clinical outcomes. The NIS does not provide longitudinal information such as inpatient and outpatient services, medications, and overall costs related to outcome. Thus, we were unable to ascertain from the NIS any changes in treatment paradigm, graft choice, graft patency, or long-term clinical outcomes over the study period. We were also unable to determine the specific type or severity of postoperative neurological or neurosurgical complications. Additionally, the clinical indication for bypass, type and location of aneurysms, neuroimaging data, and clinical decision-making involved in the selection of UIA patients for bypass cannot be extracted from this database. Another major limitation of our study is the lack of data from the NIS with respect to the use of flow diversion because endovascular aneurysm embolization procedure codes do not currently distinguish between coiling and flow diversion. Therefore, it is possible that the complexity of UIAs undergoing intervention has increased over time, concurrently with the increased frequency of UIA diagnoses, thereby potentially expanding the indications of bypass for the treatment of aneurysms that cannot be adequately occluded with flow diverters.
Conclusions
Cerebral revascularization appears to have maintained a role in the treatment of UIAs over the past two decades, despite concurrent advances in endovascular techniques and devices in this time period. The impact of the introduction and subsequent propagation of endovascular flow diversion techniques on the rates of bypass procedures performed for the treatment of UIAs appears to be limited. Further detailed studies are warranted to evaluate the riskbenefit profiles of various revascularization approaches for the treatment of UIAs not amenable to surgical clipping or endovascular therapy. While challenging in the contemporary era of aneurysm treatment, the development and maintenance of expertise in cerebral bypass techniques at high-volume centers of excellence remain necessary for the comprehensive management of particularly difficult cases.
